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…ACTGCATGCTACC… SUMMARY
We profiled gene expression and alternative splicing of non-
neoplastic colon from biopsy specimens from 445 healthy
individuals. We showed that single-nucleotide poly-
morphisms associated with these profiles are enriched in
disease-associated loci, including colorectal cancer and in-
flammatory bowel disease.
BACKGROUND & AIMS: The association of genetic variation
with tissue-specific gene expression and alternative splicing
guides functional characterization of complex trait-associated
loci and may suggest novel genes implicated in disease. Here,
our aims were as follows: (1) to generate reference profiles of
colon mucosa gene expression and alternative splicing and
compare them across colon subsites (ascending, transverse,
and descending), (2) to identify expression and splicingquantitative trait loci (QTLs), (3) to find traits for which iden-
tified QTLs contribute to single-nucleotide polymorphism
(SNP)-based heritability, (4) to propose candidate effector
genes, and (5) to provide a web-based visualization resource.
METHODS: We collected colonic mucosal biopsy specimens
from 485 healthy adults and performed bulk RNA sequencing.
We performed genome-wide SNP genotyping from blood
leukocytes. Statistical approaches and bioinformatics software
were used for QTL identification and downstream analyses.
RESULTS: We provided a complete quantification of gene
expression and alternative splicing across colon subsites and
described their differences. We identified thousands of
expression and splicing QTLs and defined their enrichment at
genome-wide regulatory regions. We found that part of the
SNP-based heritability of diseases affecting colon tissue, such as
colorectal cancer and inflammatory bowel disease, but also of
diseases affecting other tissues, such as psychiatric conditions,
182 Díez-Obrero et al Cellular and Molecular Gastroenterology and Hepatology Vol. 12, No. 1can be explained by the identified QTLs. We provided candidate
effector genes for multiple phenotypes. Finally, we provided the
Colon Transcriptome Explorer web application.
CONCLUSIONS: We provide a large characterization of gene
expression and splicing across colon subsites. Our findings
provide greater etiologic insight into complex traits and dis-
eases influenced by transcriptomic changes in colon tissue. (Cell
Mol Gastroenterol Hepatol 2021;12:181–197; https://doi.org/
10.1016/j.jcmgh.2021.02.003)
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population-based studies, using data sets with a range of
different characteristics, including variable colon anatomic
subsites, collection methods, sample sizes, sequencing
technologies, and data processing methods.1–8 A large public
transcriptome data set for non-neoplastic colon tissue from
the Genotype-Tissue Expression (GTEx) project included
samples collected from the transverse and sigmoid colon of
post-mortem subjects and included both mucosa and mus-
cularis propria.8 In most studies, the transcriptome is
assessed in terms of gene expression, however, a compre-
hensive characterization of alternative splicing (AS) has not
been performed in normal colon epithelial tissue derived
from living individuals.
AS is a post-transcriptional regulatory mechanism by
which multiple messenger RNA transcripts are produced
from a single locus, enabling enlargement of cellular func-
tions.9 More than 90% of human genes have the potential to
undergo AS.10 Common AS patterns include exon skipping,
alternative 5’ and 3’ splice sites, mutually exclusive exons,
intron retention, and alternative first or last exons.11 Based
on these predefined patterns and transcript expression
levels, different AS events and their relative abundances can
be identified for a given gene.12 In addition, by measuring
alternative excision of introns, novel and more complex
alternative splicing events can be identified.13 AS has been
assessed in multiple tissue types across several large cohorts,
including healthy8 and pathologic tissues,14–16 allowing the
association of particular AS events with phenotypes such as
age17 and cancer type.14–16 In colon tissue, AS events have
been measured in adenocarcinomas and paired adjacent
normal tissue and have been associated with colorectal
cancer (CRC) anatomic location18 and prognosis.18-20
Single-nucleotide polymorphisms (SNPs) have been
associated with gene expression (ie, expression quantitative
trait loci [eQTLs]) and AS (sQTLs), and increasingly are
identified in studies of both normal8,21-25 and malignant
tissues.26 Such associations can indicate the functional ef-
fects of SNPs at genetic risk loci, help prioritize SNPs and
genes for functional assays, serve as prognostic biomarkers,
and suggest disease mechanisms.10,26,27 In the case of
normal colon tissue, eQTL data sets have been generated,1–8
but there is no information about sQTLs derived from living
individuals.In this study, we analyzed a novel RNA sequencing
(RNA-Seq) data set of normal colon tissue biopsy specimens
including colon anatomic subsites not investigated previ-
ously (ascending, transverse, and descending). Our data set
is representative of the transcriptome of colon epithelial
cells of living subjects because all biopsy specimens were
collected from mucosa at colonoscopy. This characteristic
makes it optimal for investigating the normal physiology
across the colon, and it is relevant not only for studying the
etiologic aspects of diseases affecting this tissue, such as
CRC, but also for diseases affecting other tissues, such as
those that imply epithelial–neuronal communication28 and
those affected by perturbations of intestinal permeability.29
The aims of this study were as follows: (1) to provide a
reference transcriptomic data set for normal colon epithe-
lium by profiling gene expression and AS, (2) to identify
SNPs associated with variation in gene expression and AS
(ie, QTLs), (3) to list traits for which identified QTLs
contribute to SNP-based heritability, (4) to prioritize
candidate effector genes, and (5) to provide a web-based
resource to visualize the expression profiles and QTLs.
Results
The University of Barcelona and University of Virginia
genotyping and RNA Sequencing Project: A Novel Reference
Data Set for Colon Tissue Transcriptome Analysis
The University of Barcelona and University of Virginia
genotyping and RNA sequencing project (BarcUVa-Seq)
cross-sectional study included 485 adult volunteers found to
have an endoscopically healthy colon (ie, a normal colon
without polyps or other lesions) from whom we collected
superficial colon biopsy specimens and blood samples. Bulk
RNA was isolated from biopsy samples and sequenced in
several batches. Subjects were genotyped using the Illumina
(San Diego, CA) OncoArray 500K beadchip,30 and genome-
wide SNPs were imputed. After filtering the data to select
for individuals with high-quality RNA-Seq and genotype
samples (see theMaterials andMethods section), we included
data from 445 individuals, among whom 283 were female
(64%). Biopsy specimens were obtained from sites along the
ascending (n ¼ 138; 31%), transverse (n ¼ 143; 32%), and
descending (n¼ 164; 37%) colon (Table 1). We profiled gene
expression and alternative splicing and identified cis-acting
eQTLs and sQTLs (see the Materials and Methods section).
Table 1.BarcUVa-Seq Data Set Descriptive




Age, y, means ± SD 60 ± 7.44
Colon anatomic location overall
and stratified by sex, n (%)






Descending (left) 164 (36.9)
Female 107 (65.2)
Male 57 (34.8)
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Expression was analyzed based on GENCODE (E;BL-EBI,
Hinxton, UK) release 19 annotations.31 After filtering out
features with low or no expression, 21,281 genes and
104,769 transcripts remained (see the Materials and
Methods section). Gene and transcript abundances of in-
terest can be visualized online (see the Colon Transcriptome
Explorer [CoTrEx] section). We considered 13,243 AS
events in 6178 genes after applying filters (see AS events
annotations in Supplementary Table 1). We categorized AS
events as follows: alternative first exons (30%), exon skip-
ping (24%), alternative 3’ splice-site (12%), alternative 5’
splice-site (12%), intron retention (10%), alternative last
exons (10%), and mutually exclusive exons (1%) (Figure 1,
Table 2). Most genes had AS events from 1 or 2 categories,
and few had AS events from up to 6 categories. In addition,
as a complementary AS metric, we computed the abun-
dances of 269,586 alternatively excised introns that were
grouped in 73,313 clusters. Some introns (23%) were novel
and 77% were annotated in 15,912 genes. We filtered in-
trons by low expression or low complexity and considered
only 42,808 intron clusters annotated in 8953 genes for
sQTL analysis (see the Materials and Methods section).
Transcriptomic Profiles Differ Between Colon
Subsites
We aimed to identify genes and splicing features that
were expressed differentially across colon subsites, situ-
ating the transverse colon as an intermediate phenotype
(see the Materials and Methods section). Overall, 4430
genes were expressed differentially between ascending,
transverse, and descending subsites (family-wise error rate
[FWER], 0.05), with absolute log fold changes of up to 3.7
(Figure 2A). Hierarchical clustering of the top 30 genes with
the smallest FWER showed the transverse colon clustered
with descending colon (Figure 2B). Full differential gene
expression results are listed in Supplementary Table 2. Next,
we tested whether genes expressed differentially across
subsites were enriched for features in a wide array of
curated gene sets, signatures, functional pathways, andontologies. We found enrichment in a gene set associated
with normal colon tissue transformation into adenoma, in
pathways involved in drug metabolism, and in other bio-
logical processes such as antimicrobial humoral response.
Full enrichment results are listed in Supplementary Table 3.
For splicing, we found 236 genes with different relative
abundances of AS events (false-discovery rate [FDR], 0.05)
(Supplementary Tables 4 and 5) and 280 genes with
different relative abundances of excised introns between the
ascending and descending colon (FDR, 0.05)
(Supplementary Table 6).
Identification of eQTLs and sQTLs
We identified 11,739 eQTLs (Q value  0.05) including
11,427 unique SNPs (eSNPs) associated with the expression
of 11,739 genes (eGenes) (Supplementary Table 7). Most
eSNPs were associated with a single eGene, but we found
eSNPs associated with up to 6 eGenes. Neither the location
of the eSNPs relative to the gene transcription start site
(TSS) nor the allele frequency were associated with the
eSNP effect (Figure 3). eQTLs can be explored on the CoTrEx
web application (see the Colon Transcriptome Explorer
section). Full eQTL summary statistics are publicly available
(see the Data availability statement). In addition, we per-
formed eQTL interaction analysis for colon subsites
(ascending vs descending) and found 26 eQTLs with a Q
value of 0.05 or less (Supplementary Table 8). The eQTL
rs6684275-RIMKLA showed an inverse association in the
ascending colon compared with the descending colon
(Figure 4).
Next, we mapped 1125 sQTLs (Q value  0.05) including
1122 unique SNPs (sSNPs) associated with 1125 genes
(sGenes) (Supplementary Table 9). The proportions of AS
categories among SNP-associated AS events were similar to
those found for total AS events (Table 2). Although we found
82% of sGenes among eGenes, only 8% of sGenes shared the
same genetic variants with eGenes (6%) or harbored vari-
ants in high linkage disequilibrium (LD R2 > 0.8) with
eSNPs (2%) (Figure 5A). In addition, we identified an
additional set of 1062 sQTLs (Q value  0.05) of 1058
sSNPs associated with clusters of excised introns in 1062
genes (Supplementary Table 10) and observed that 40% of
these sGenes were in common with sGenes associated with
AS events. sQTLs can be explored on the CoTrEx web
application (see Colon Transcriptome Explorer section), and
full summary statistics are publicly available (see Data
availability statement).
Replication and Meta-Analysis With GTEx
We performed replication and meta-analyses using data
from the GTEx project v8.8 For replication analysis, we used
samples from the sigmoid and transverse colon (n ¼ 318
and n ¼ 368, respectively). For the replication of eQTLs, we
downloaded the list of GTEx eQTLs (see the Materials and
Methods section). For the replication of sQTLs we used
GTEx transcript expression data for computing AS events as
well as SNPs for computing sQTLs using the same approach
considered for BarcUVa-Seq data (Supplementary Tables 11
Figure 1. Alternative splicing events. (A) Scheme of gene and alternatively spliced transcripts structure in 7 AS categories:
alternative first exons (AF), exon skipping (SE), alternative 3’ splice-site (A3), alternative 5’ splice-site (A5), intron retention (RI),
alternative last exons (AL), and mutually exclusive exons (MX). Constitutive exons (ie, those maintained in all processed
transcripts after splicing) are shown in gray. Exons in red or gold alternatively are present in processed transcripts after
splicing. Dashed line indicates different splicing processing for a gene. (B) Frequency of AS events and genes by AS category.
One gene can be processed according to different AS categories.
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BarcUVa-Seq and GTEx colon data sets and computed the p1
statistic32 (Figure 6). For eQTLs, a higher replication value
(p1 ¼ 0.76) was obtained for GTEx transverse colon than for
sigmoid colon (p1 ¼ 0.56). For sQTLs the same replication
statistic was obtained for both GTEx colon tissue data sets
(p1 ¼ 0.67).
We performed a meta-analysis of BarcUVa-Seq eQTLs
with the full GTEx v8 data set (n ¼ 49 tissues) using a
multivariate adaptive shrinkage approach.33 Hierarchical
clustering of pairwise correlations on the resulting effect
sizes showed that BarcUVa-Seq eQTLs from colonic mucosa
clustered with GTEx eQTLs from transverse colon and ter-
minal ileum (Figure 7A). The correlations between BarcUVa-
Seq eQTL effect sizes and all GTEx tissues showed that
transverse colon, terminal ileum, stomach, minor salivaryTable 2.Description of AS Events and Genes by AS category
Event category Total AS events, n (%) Total g
SE 3235 (24.43) 2542
AF 4023 (30.38) 2146
A3 1627 (12.29) 1378
A5 1579 (11.92) 1344
RI 1327 (10.02) 1022
AL 1292 (9.76) 785
MX 160 (1.21) 148
Overall 13,243 (100.00) 6170
NOTE. A given gene can have AS events from up to 6 categor
AF, alternative first exons; AL, alternative last exon; A3, alter
retention; MX, mutually exclusive exons; SE, exon skipping.gland, and kidney cortex are the GTEx tissues with highest
correlation (r > 0.7) (Figure 7B).Annotation and Functional Enrichment Analyses
We observed eSNPs and sSNPs distributed in patterns
similar to each other across the following genomic regions:
introns, intergenic regions, upstream and downstream gene
regions, 3’ and 5’ untranslated regions and splice regions
(including donor and acceptor variants). Intronic variants
were the most common from both types of SNPs. Intergenic
and upstream regions harbored higher proportions of eSNPs
than sSNPs, and splice and untranslated regions harbored
higher proportions of sSNPs than eSNPs (Figure 5B).
Functional consequences also were assessed: most SNPs










native 3’ splice-site; A5, alternative 5’ splice-site; RI, intron
Figure 2. Differential gene expression profiles across colon anatomic subsites. (A) Volcano plot showing the distribution
of gene log fold changes and statistical significance. Points above the horizontal dashed line represent genes considered
significantly differentially expressed (FWER  0.05). Points in red and blue color represent genes over (red) and underex-
pressed (blue) following a consistent trend from ascending to descending colon (ie, overexpressed in transverse relative to
ascending colon and overexpressed in descending relative to transverse). (B) Heatmap showing the expression profiles of the
top 30 differentially expressed genes across colon subsites ranked by FWER-adjusted P values. Hierarchical clustering shows
the similarity between genes (rows) and samples (columns) based on Euclidean distances.
2021 Genetic Effects on Colon Transcriptome 185classified as nonsense, start loss, frameshift, canonical splice
site, missense, or synonymous variants (Supplementary
Table 13).
Next, we performed enrichment analysis at regulatory
regions (open chromatin regions, active enhancers, super-
enhancers, and transcription factor binding sites) using data
derived from colon cell lines as well as from normal andFigure 3. eQTLs features. (A) Distribution of distances betwee
bution of absolute beta values (slope associated with the nom
frequencies (MAF). These variables were not correlated (r ¼ 0.1cancerous colon tissue. We found significant enrichment (P
value  .05) in all types of regulatory regions for both
eSNPs and sSNPs. In addition, we looked for enrichment in
target sites distributed across the genome of 170 RNA-
binding proteins (RBPs). The top 20 RBPs with the lowest
P values for eSNP enrichment are included in Figure 8A. Of
those RBPs, 15 also were among the top 20 RBPs mostn eSNPs location and corresponding eGenes TSS. (B) Distri-
inal P value of association) of eQTLs and eSNPs minor allele
4).
Figure 4. Example of eQTLs interacting with colon sub-
site. Distribution of expression level (inverse normal trans-
formed trimmed means of M values) of RIMKLA by rs6684275
genotype and colon subsite.
186 Díez-Obrero et al Cellular and Molecular Gastroenterology and Hepatology Vol. 12, No. 1enriched for sSNPs. In both cases, the heterogeneous nu-
clear ribonucleoprotein C was the RBP with the most sig-
nificant enrichment. The RBPs with highest enrichment
values for sSNPs are included in Figure 8B. We observed
sSNPs enriched at binding sites of spliceosome constituents
such as the splicing factor U2 small nuclear RNA auxiliary
factor 1. Full enrichment results are listed in Supplementary
Table 14.
Phenotype Heritability Enrichment and
Colocalization Analyses
To quantify the ability of BarcUVa-Seq QTLs to explain a
phenotype’s genetic risk loci, we analyzed eSNPs/sSNPs in
the context of their potential contribution to total SNP-basedFigure 5. Colocalization among sSNPs and eSNPs and gen
patterns among sSNPs and eSNPs in common genes according
at specific genomic regions, note that the plot is gapped betwee
the differences in the categories with the lowest representationheritability estimates of multiple complex traits. SNP-based
heritability is the heritability of traits captured by SNPs in a
SNP array in the context of a genome-wide association study
(GWAS). We performed SNP-based heritability enrichment
tests in 63 complex diseases and traits that we considered a
priori to influence or be influenced by colon homeostasis.
We observed that eSNPs were enriched in the SNP-based
heritability estimation of 20 diseases or traits after Bon-
ferroni adjustment (P value  8  10-4) and 31 diseases or
traits at an unadjusted P value  .01. SNP-heritability en-
richments for 33 traits and diseases are included in
Figure 9A, and full results are listed in Supplementary
Table 15. BarcUVa-Seq eSNPs explained 17% of the total
SNP-based heritability of CRC (P value ¼ 9  10-8), which
accounts for 10% of the phenotype (based on a recent
GWAS study34). Interestingly, eSNPs also were enriched in
the SNP-based heritability estimation of
psychiatric–neuronal disease, such as schizophrenia, bipolar
disorder, and multisite chronic pain. BarcUVa-Seq sSNPs
were enriched in the SNP-based heritability estimation of 10
diseases and traits at a P value  .01, but no enrichments
were statistically significant after Bonferroni adjustment
(Figure 9B shows 33 representative traits or diseases,
Supplementary Table 15 has the full list of results).
BarcUVa-Seq sSNPs explained 3% of the total SNP herita-
bility of ulcerative colitis (P value ¼ .02), which accounts for
13% of the phenotype (Figure 9B).
Subsequently, to nominate candidate genes at GWAS-
identified genetic risk loci, we performed colocalization
analyses for the complex traits and diseases that passed
Bonferroni correction for SNP-based heritability analysis for
BarcUVa-Seq eSNPs. The regional colocalization probability
is used as a proxy for the gene’s causality, that is, to quantify
the probability that an eQTL and a GWAS signal share the
same causal variant.35 In the case of CRC, we identified 13
genes with regional colocalization probability greater thanomic region annotation. (A) Percentages of colocalization
to measures of LD R2. (B) Percentages of eSNPs and sSNPs
n 15% and 30% and rescaled between 30% and 60% to show
. UTR, untranslated region.
Figure 6. Replication anal-
ysis of eQTLs/sQTLs with
GTEx v8 colon data. The
value of the p1 statistic is
shown. The distribution of P
values is shown for (A)
transverse colon eQTLs, (B)
sigmoid colon eQTLs, (C)
transverse colon sQTLs, and
(D) sigmoid colon sQTLs.
Figure 7. Meta-analysis with GTEx v8 tissues. (A) Clustering of BarcUVa-Seq and GTEx v8 tissues based on pairwise
Spearman correlation of eQTL effect sizes derived from mashr meta-analysis. We only considered significant (FDR  0.05) and
active (local false sign rate [LFSR]  0.05) eQTLs. (B) Spearman correlation of eQTL effect sizes between BarcUVa-Seq and
GTEx v8 tissues. eQTL effect sizes were derived from mashr meta-analysis. We only considered significant (FDR  0.05)
and active (LFSR  0.05) eQTLs.
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Figure 8. Enrichment of eSNPs/sSNPs in binding sites across the genome of RBPs. (A) The top 20 RBP with the lowest
enrichment P values for eSNPs. (B) The top 20 RBPs with the highest enrichment values for sSNPs (P value < .05).
Figure 9. BarcUVa-Seq QTL enrichment results for total SNP heritability of 33 complex traits and diseases related to
colon tissue. (A) Proportion of total SNP heritability explained by eSNPs is shown on the x axis, along with error bars. The size
of the points indicates the percentage of the total SNP heritability out of the total heritability of the phenotype. (B) Proportion of
total SNP heritability explained by sSNPs is shown on the x axis, along with error bars. The size of the points indicates the
percentage of the total SNP heritability out of the total heritability of the phenotype.
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2021 Genetic Effects on Colon Transcriptome 1890.9, including known risk genes such as COLCA1 and
COLCA2,6 as well as other less-well-described genes such as
ANKRD36. In the case of inflammatory bowel disease, we
identified 6 genes with a regional colocalization probability
greater than 0.9, such as IRF8 and RGS14 (Figure 10). Full
results are available in the Supplementary Data.
Colon Transcriptome Explorer
Gene and transcript abundances for the BarcUVa-Seq
data set, as well as eQTLs/sQTLs, have been loaded into
the web-based visualization resource CoTrEx. This tool fa-
cilitates searches for genes and transcripts of interest for
their visualization in customizable plots, such as a strip
chart, heatmap, and principal component analysis (PCA)
plots. The interactive application includes different options
for filtering and coloring the data by covariates. Figure 11
shows an example in the Expression tab. CoTrEx is freely
available online at http://barcuvaseq.org/cotrex.
Discussion
In the present study we analyzed a large data set (Bar-
cUVa-Seq) comprising germline SNPs and transcriptome
profiles from mucosal biopsy specimens of ascending,
transverse, and descending colon collected from 445
healthy living individuals. Differential expression patterns
were identified across colon subsites. We profiled 11,739
eQTLs comprising 11,427 unique SNPs associated with the
expression of 11,739 genes. In addition, we identified
13,243 AS events from 7 distinct AS categories and identi-
fied 1125 AS events in 1125 genes associated with 1122
unique SNPs (sQTLs). These eQTLs/sQTLs frequently were
intronic and enriched in regulatory regions. We showed
how these are useful for annotation of GWAS-identified risk
loci and prioritization of candidate effector genes. Moreover,
we replicated and meta-analyzed our QTLs with GTEx v8
data. Finally, we built an interactive web resource to explore
the expression profiles and QTLs of the BarcUVa-Seq data
set.
In contrast to BarcUVa-Seq, the GTEx project provided
RNA-Seq data on sigmoid and transverse colon tissue from
post-mortem subjects and extracted RNA from full-
thickness and muscularis-only sections.8,36 Our novel
BarcUVa-Seq data set overcomes some of the limitations of
the GTEx colon data sets. BarcUVa-Seq samples were
collected as superficial mucosal biopsy specimens in living
subjects undergoing colonoscopy, which provide an optimal
representation of the normal physiology of the colon
epithelium. Moreover, they included subsites of the large
intestine not assessed previously. Together with the
enrichment of colon epithelial cells in superficial biopsy
specimens, inclusion of ascending, transverse, and
descending colon samples make BarcUVa-Seq a unique co-
lon transcriptome data set.
Next-generation RNA-Seq data provide estimates of AS.
Although long-read sequencing technologies can provide
transcriptomic profiles with full-length isoform information,
such technologies have lower base-level fidelity and are less
feasible in large population-based studies at their currentcost.11 In this study we used 2 complementary methods to
provide a comprehensive profile of AS. The frequencies of
genes with specific AS patterns that we identified in colon
tissue are similar to those described in other tissues, where
genes with exon skipping events were the most frequent.17
Predicting AS events helps generate hypotheses about spe-
cific molecular mechanisms involved in post-transcriptional
modifications. In contrast to profiling individual transcripts
to characterize the transcriptome, AS events group tran-
scripts with similar structure. However, the profiles of an-
notated AS events are sensitive to the choice of transcript
annotations,11 and other measures of AS, such as clusters of
excised introns, complement the characterization of AS
events.13
Regarding colon location, transcriptomic differences be-
tween subsites in normal colon have been described pre-
viously,37 including gene expression differences in genes
from the cytochrome P450 family. In addition, different AS
events have been identified between CRC tumors located in
the ascending and descending colon.38 Indeed, tumor dis-
tribution across the colon has been associated with differ-
ential mutation and immune profiles, prognosis, and
treatment response.39,40 In this study, we identified a subset
of genes expressed differentially between colon subsites
that are involved in molecular pathways related to lipid,
xenobiotic, and drug metabolism, and a subset of genes
involved in antimicrobial response. We observed that the
gene expression profile of transverse colon tissue was more
similar to the descending than to the ascending colon, which
was unexpected based on embryologic origin and adult
blood supply. Differential gene expression across the colon
may reflect differences in cell type composition because we
find gene markers of different cell types of the colon
epithelium shown by single-cell RNA-Seq studies.41-43 For
instance, using our data, we confirmed that goblet cell
markers defined elsewhere,41 such as MUC2 and TFF3, are
overexpressed in descending colon (Supplementary
Table 2), which supports previous findings that have
shown that goblet cell content increases caudally from du-
odenum to distal colon.44 Differential expression also may
be influenced by differential exposure owing to variability in
luminal content along the length of the colon, including
microbial communities.43
We identified eQTLs and sQTLs assumed to participate
in the transcriptional regulation of colon epithelium via cis
mechanisms. These had strong replication in the transverse
colon from GTEx v8 and were more similar to tissues with a
high proportion of mucosa (eg, terminal ileum, stomach, and
salivary gland) than others from GTEx v8, showing the
robustness of BarcUVa-Seq data. The lower replication value
in sigmoid colon may be owing to the higher proportion of
muscularis in this tissue.8,36 We found fewer sGenes than
eGenes, partly because the number of genes that showed
splicing variability was lower than genes with expression
variability. In addition, we had lower power to detect
expression for transcripts than for genes at our depth of
coverage. We found similar distributions of eSNPs/sSNPs
around gene TSSs, as well as across estimated effect sizes,
genomic locations, and functional consequences. We
Figure 10. The top eQTLs of the genes with the highest regional colocalization probability for CRC and inflammatory
bowel disease. (A) Expression level (inverse normal transformed trimmed means of M values [TMMs]) of COLCA2 by genotype
of the eSNP rs11213820. (B) Expression level (inverse normal transformed TMMs) of IRF8 by genotype of the eSNP
rs16940186.
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reported elsewhere.24,25 Although they can colocalize,
eQTLs and sQTLs usually are independent.27 sQTLs add
information to eQTLs as they associate SNPs with changes in
relative use of specific sets of transcripts sharing a common
structure and post-transcriptional mechanism.
In this study, we showed that regulation of gene
expression and AS is associated with tissue-specific epige-
netic variations, including chromatin remodeling and his-
tone modifications.45 The dysregulation of these features
has been associated with initiation and progression of dis-
eases such as CRC.45,46 We showed that normal colon
eSNPs/sSNPs are present at many important regulatory
regions marked by epigenetic signatures, such as open
chromatin and proximal enhancers of both normal and
malignant colon tissue. In addition, we identified specific
RBPs and transcription factors as potential regulators of AS
in normal colon.
We provide a comprehensive profile of AS for normal
tissue along colon subsites in living subjects. We described
differential gene expression and splicing between the
ascending and descending normal colon, which involved
genes of immune response and drug metabolism. We
expanded the number of colon QTLs and assessed eQTL
interaction with colon subsites. In addition, we observed
that colon eQTLs/sQTLs contributed to the SNP-based her-
itability of brain-related traits and disease, supporting a
model of epithelial–neuronal communication along the
gut–brain axis.28 Thus, our QTL catalog may be of potential
interest for researchers investigating traits and diseasesthat do not primarily affect the colon, but other organs. It is
important to note that these results could reflect a common
regulation of expression between tissues. In addition,
colocalization alludes to potential molecular mechanisms
associated with risk loci, but may not prove to be directly
causal.
Overall, our findings provide evidence of the regulation
of gene expression and alternative splicing in the colon as
potential underlying mechanisms of genetic risk loci and
should serve as a rich resource for the research community.Methods
Sample Collection
Subjects included in the study (n ¼ 445; 64% females)
had a mean age of 60 years, were almost all of European
ancestry, and received an indication for colonoscopy after a
positive fecal immunochemical test result (hemoglobin
level, >20 mg Hb/g) or by direct referral by their medical
doctor. Subjects had no lesions at colonoscopy and no his-
tory of polyps or CRC. Non-neoplastic colon mucosa biopsy
specimens were obtained endoscopically from the
ascending (n ¼ 138; 31%), transverse (n ¼ 143; 32%), and
descending (n ¼ 164; 37%) colon (Table 1). Peripheral
blood samples also were collected. Informed consent was
obtained from all participants. The corresponding study
protocol was approved by the Bellvitge University Hospital
Ethics Committee (PR073/11 and PR286/15) and followed
national and international directives on ethics and data
protection. More information about the BarcUVa-Seq project
Figure 11. Overview of the expression tab of CoTrEx. As an example, the transcript expression values and relative abun-
dances of the TP53 gene are shown, along with different display options.
2021 Genetic Effects on Colon Transcriptome 191can be accessed online at https://barcuvaseq.org. All au-
thors had access to the study data and reviewed and
approved the final manuscript.RNA-Seq Library Preparation and Sequencing
RNA was extracted from frozen tissue using the mirVana
kit (Thermo Fisher Scientific, Waltham, MA) after homoge-
nization using the Minilys bead mill (Bertin Instruments,
Montigny le Bretonneux, France). The RNA was DNAse
treated and concentrated using the RNA Clean and
Concentrator-5 kit (Zymo Research, Irvine, CA). Quantifica-
tion of total RNA was executed using a Qubit Fluorometer
(Invitrogen, Walthan, MA). An Agilent (Santa Clara, CA)
2100 Bioanalyzer or TapeStation was used to assess quality.
For library preparation, the Illumina TruSeq Stranded Total
RNA Library Prep Gold kit was used. Libraries were tagged
with unique adapter indexes. Final libraries were validated
on the Agilent 2100 Bioanalyzer, quantified via quantitativepolymerase chain reaction, pooled at equimolar ratios,
diluted, denatured, and loaded onto an Illumina HiSeq 2500
(high-output mode), for batches 1–7, or a NovaSeq 6000, for
batch 8, instruments using a paired-end flowcell.RNA-Seq Data Processing
Low-quality bases, sequencing adapters, and ribosomal
RNA of raw sequences were trimmed from RNA-Seq reads
using BBTools suite (Joint Genome Institute, Berkeley,
CA).47 FastQC (Babraham Bioinformatics, Cambridge, UK)48
was used for quality control. Trimmed reads were aligned
against human transcriptome using the Genome Reference
Consortium human reference 37 assembly (GRCh37/hg19)
with the Spliced Transcripts Alignment to a Reference
(STAR, Cold Spring Harbor Laboratory, Cold Spring Harbor,
NY) software in 2-pass mode49 using GENCODE (EMBL-EBI,
Hnxton, UK) release 19 annotations, which include a total of
57,952 genes and 196,667 transcripts.31 We only included
192 Díez-Obrero et al Cellular and Molecular Gastroenterology and Hepatology Vol. 12, No. 1samples with a depth of coverage greater than 10 million
mappable paired-end reads, a multimapping rate lower than
15%, and a unique mapping rate greater than 80%. The
mean library size was 32M (SD, 8.5M). Gene and transcript
expression were quantified with RSEM (University of Wis-
consin-Madison, Madison, WI).50 Genes and transcripts with
fewer than 6 and 3 counts, respectively, in less than 10% of
the samples were considered not expressed and filtered out.
Trimmed mean of M values were computed from counts to
correct for library size and RNA composition.
Genotype Data Processing
Genotyping of approximately 400,000 SNPs was per-
formed with the Illumina OncoArray BeadChip.30 We only
included samples with a genotyping rate greater than 95%.
The following aspects also were assessed before imputation:
duplication and relatedness greater than 0.8, missing rate
per SNP greater than 0.1, missing rate per sample greater
than 0.1, sex concordance (genetic and reported sex), het-
erozygosity: means ± 4 SD and Hardy–Weinberg disequi-
librium P value less than 1 x 10-4. We obtained allelic
dosages from 39,117,105 and 1,228,035 SNPs for auto-
somes and chromosome X, respectively, using SHAPEIT
(University of Oxford, Oxford, UK)51 for phasing and Mini-
mac 3 (University of Michigan, Ann Arbor, MI)53 for impu-
tation with The Haplotype Reference Consortium panel on
the Michigan Imputation Server.52 SNPs with an imputation
quality of R2 less than 0.7 or minor allele frequency (MAF)
less than 1% were excluded, resulting in 6,804,675 and
183,788 SNPs for autosomes and chromosome X, respec-
tively. Allelic dosages were used for subsequent QTL ana-
lyses. SNP IDs were annotated using dbSNP version 142.53
Principal components of genetic data were obtained with
PLINK 1.9 (Complete Genomics, Mountain View, CA).54 We
checked that both genotype and RNA-Seq samples had been
labeled correctly and belonged to the same individual using
Picard Tools CheckFingerprint (Broad Institute, Cambridge,
MA).
Alternative Splicing Profiling
For quantifying AS, we used 2 complementary methods
that provide the relative abundance (ie, percent splicing
index [PSI]) of specific AS features. Seven types of AS events
were determined based on GENCODE version 19 annota-
tions with SUPPA2 (Catalan Institution for Research and
Advanced Studies, Barcelona, Spain).12 In this case, the PSI
reflects the proportion of transcripts of a given gene
showing a specific AS event (ie, inclusion transcripts) of the
total transcripts of the gene.11 This metric was calculated
with SUPPA2 for each AS event by dividing the expression
levels of the inclusion transcripts by the total expression
levels of all transcripts of the gene. We kept AS events in
which the median PSI for all samples was between 0.05 and
0.95 (see AS events annotations in Supplementary Table 1).
As a complementary approach, we used LeafCutter (Stan-
ford University, Stanford, CA)13 following the analysis pro-
cedure described elsewhere8 to compute the relative
abundance of alternatively excised introns.Differential Gene Expression and Splicing
Analysis
Differential gene expression analysis was performed
using a quasi-likelihood F-test implemented in the R pack-
age edgeR (Garvan Institute of Medical Research, Parkville,
Australia).55 Ward’s minimum variance method with
Euclidean distances was used for hierarchical clustering. For
differential splicing analysis, normalized PSI values of AS
events were fitted in a linear model adjusted for sex, age,
and sequencing batch using the R package limma (Univer-
sity of Melbourne, Parkville, Australia).56 The function
diffSplice was used to perform an F test to find the differ-
ences between AS event log-fold-changes of a gene and yield
a single gene-level P value. T tests for individual AS events
also were performed with diffSplice. Differential use of
excised introns was performed with LeafCutter,13 adjusting
for sex, age, and sequencing batch. Functional enrichment
analysis was performed with FUMA gen2func (University
Amsterdam, Amsterdam, The Netherlands)57 using differ-
entially expressed genes with FWER of 0.05 or less. FWER
values were estimated for correcting for multiple testing
using a Bonferroni correction.
eQTL/sQTL Mapping
We mapped QTLs within 1 Mb of the TSSs for given
genes and assumed QTLs influenced expression of nearby
genes via cis mechanisms. For QTL identification we used
FastQTL (University of Geneva Medical School, Geneva,
Switzerland) version 2.0.58 We applied an inverse normal
transformation on gene trimmed means of M values and
PSI values, which mitigates the effect of outliers and
normalizes the expression distribution across samples. We
adjusted the models for age, sex, sequencing batch, tissue
anatomic location, genetic ancestry (2 principal compo-
nents), and probabilistic estimation of expression re-
siduals factors,59 which capture the effects of unknown
confounding variables. We chose the number of probabi-
listic estimation of expression residuals factors that
maximized the discovery of eGenes/sGenes. FDR (Storey
and Tibshirani procedure) was computed with R package
qvalue (Princeton University, Princeton, NJ).60 For colon
subsite eQTL interaction analysis we used the FastQTL
version 2.0 interaction mode.57
Replication and Meta-Analysis With GTEx Data
For replication analysis, we estimated p1
33 with the R
package qvalue.60 This statistic reflects the proportion of
true positives among BarcUVa-Seq QTLs that also were
detected by the corresponding QTL analysis in GTEx v8.
Following a common approach described elsewhere,8 we
only included associations involving the SNP with the
lowest P value for each gene to avoid including many SNPs
in LD. For meta-analysis, full GTEx v8 eQTL summary
statistics (n ¼ 49 tissues) were downloaded from the
Google Cloud Platform (Mountain View, CA) under gtex-
resources. We used a multivariate adaptive shrinkage
approach using the R package mashr (University of Chi-
cago, Chicago, IL)33 following the same analytic pipeline
2021 Genetic Effects on Colon Transcriptome 193described elsewhere.8 Effect size estimates and local false
sign rate output by mashr were used as metrics of QTL
magnitude and activity, respectively. A local false sign rate
less than 0.05 was used as a threshold for significant QTL
activity.
Annotation and Functional Enrichment Analysis
For the annotation of genomic regions and classifica-
tion of variants according to their functional consequence
we used the ENSEMBL Variant Effect Predictor (EMBL-
EBI, Hinxton, UK).61 We used the –pick flag to extract a
single annotation per variant following an ordered set of
criteria to prioritize annotations. For functional enrich-
ment analysis in regulatory regions distributed across the
genome (Supplementary Table 14), we compiled a list of
publicly available regions relevant for colon tissue from
different studies (ie, active enhancers,46 variant enhancer
loci,46 open chromatin sites,34,46 superenhancers,62 and
transcription factor binding sites63). Regions from multi-
ple samples of the same assay type were joined. In addi-
tion, we downloaded RNA binding protein sites, including
splicing factor binding sites, from CLIPdb (Tsinghua Uni-
versity, Beijing, China).64 We used GREGOR (University of
Michigan, Ann Arbor, MI),65 which defines enrichment
(fold change) as the ratio between the number of observed
vs expected SNPs overlapping the regulatory regions. This
approach accounts for the number of LD proxies, gene
proximity, and MAF.
Phenotype Heritability Enrichment and
Colocalization Analyses
For the SNP-based heritability enrichment analysis
(partitioned heritability analysis) of eSNPs/sSNPs among
disease-/trait-associated loci, we applied linkage disequi-
librium score regression using the software LD SCore
(Broad Institute of MIT, Cambridge, MA)66 with baselineLD
model. A list with the GWAS summary statistics used for this
analysis and related information can be found in
Supplementary Table 15. Total SNP heritability for the
tested phenotypes was estimated in observed scale for
continuous traits and in liability scale for binary traits, using
LD score regression from a total of 1,217,312 SNPs with a
MAF greater than 0.05 in HapMap phase 3 populations
(NHGRI, Bethesda, MD).66 Under the null hypothesis of all
SNPs contributing equally to the total SNP-based heritabil-
ity, we would expect that the 1122 sSNPs and 11,427 eSNPs
identified in this study explain approximately 0.09% and
0.94%, respectively, of estimated total SNP heritability.
Population prevalence and lifetime risk in the case of CRC
was curated from the literature. For colocalization we used
the fastENLOC (University of Michigan)35 approach. We
computed Z-score–derived posterior inclusion probabilities
for GWAS summary statistics with TORUS (University of
Michigan)67 and assigned LD blocks to each locus using the
references defined elsewhere.68 We performed multi-SNP
fine-mapping analysis of eQTLs with DAP-G (University of
Michigan).69Web Application
The web-based visualization resource CoTrEx was
developed with the RStudio platform Shiny (Boston, MA)70
using open-source software.Data Availability
The RNA-Seq and SNP data that support the findings of
this study as well as the sample covariates are available
from the European Genome-phenome Archive under
accession number EGAS00001004891. Complete summary
statistics (including all FastQTL nominal pass results) for all
QTLs identified in this study are available from the Digital
Repository of the University of Barcelona at http://hdl.
handle.net/2445/172697. Top-QTLs per gene are available
in Supplementary Tables 7, 9, 10, 11, and 13.References
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